In accordance with the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, NATCO Pharma has informed about the following Regulatory Update: NATCO Pharma Limited announces that Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement of the U.S. patent litigation related to generic Ozempic (Semaglutide). NATCO and Mylan are partnered on the development of generic Ozempic products. The terms of the settlement are confidential. NATCO’s manufacturing partner is Stelis.
The above information is a part of company’s filings submitted to BSE.
